I Agree

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms of Use.

PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Tiziana Life Sci PLC (TILS)

Tiziana Life Sci PLC

Discounted exercise prices of outstanding warrants
RNS Number : 8348H
Tiziana Life Sciences PLC
20 November 2018
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Tiziana Announces temporary reduction to exercise prices of outstanding warrants

London, 20 November 2018 - Tiziana Life Sciences plc (AIM: TILS) (the "Company" or "Tiziana"), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announced earlier today that it had priced its underwritten initial public offering in the United States (the "Offering"). The closing of the Offering is expected to occur on 23 November 2018, subject to customary closing conditions.

In light of these developments and to potentially reduce the number of warrants outstanding, the Company has resolved to allow the holders of its warrants to exercise at reduced exercise prices in the period commencing on the date of this announcement and ending on 30 November 2018.

The Company currently has the following outstanding warrants:

Class of Warrant

Current exercise price

Current expiry date

Reduced exercise price if exercised prior to 5pm on 30 November 2018

Class A

£1.05

31/12/2021

£0.75

Class C

£1.05

31/12/2021

£0.75

Class D

£1.05

31/12/2021

£0.75

Class E

£2.50

31/12/2021

£0.80

Class F

£2.50

31/12/2021

£0.80

Class G

£1.60

20/11/2022

£0.78

Class H

£1.60

11/12/2023

£0.78

Class I

£1.60

15/12/2023

£0.78

Class J

£1.60

15/01/2024

£0.78

Class K

£1.60

22/01/2024

£0.78

Class L

£1.00

05/03/2023

£0.75

Class M

£0.80

19/04/2023

£0.75

Special class

£1.60

15/01/2024

£0.78


All warrant holders will receive individual email notifications of this change in the next 24 hours. Should warrant holders decide not to take any action then the original terms, conditions and final exercise dates will remain unaltered in respect of any warrants not exercised prior to 5pm on 30 November 2018.

All ordinary shares issued as a result of warrant holders exercising warrants at the reduced exercise prices will be aggregated at the end of the exercise period and the Company will make an application to have the ordinary shares admitted to trading on AIM on 4 December 2018.

The person who arranged for the release of this announcement on behalf of the Company was Tiziano Lazzaretti, Chief Financial Officer of Tiziana.

For further enquiries:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder 

+44 (0)20 7493 2853

 

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner 

 

+44 (0)20 7213 0883

Stockdale Securities Limited (Broker)

Andy Crossley / Antonio Bossi

 

+44 (0)20 7601 6125

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBLBJTMBMBTJP
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close